We report a rare case of a 64-year-old female with metachronous secondary primary left occult breast cancer initially presenting right axillary lymph node metastases. The patient, who had received breast-conserving therapy for left breast cancer at another hospital about 4.5 years ago, came to our hospital complaining of right axillary node swelling. After both breast and systemic examination, she received complete right axillary lymph node dissection. Just after the operation, she was diagnosed with right occult breast cancer by a review of the right axillary lymph nodes and previous left breast cancer. She was followed by radiation and systemic chemoendocrine therapies. One year after axillary lymph node dissection, mammography and ultrasonography showed a new lesion in her left breast. Core needle biopsy revealed similar findings to right axillary lymph node metastasis. After salvage surgery, the diagnosis was revised. We recommend that patients without clinical findings except for axillary lymph node metastasis, especially post-breast-conserving surgery followed by radiation therapy, should be considered not only as having ipsilateral but also contralateral occult breast cancer. If there is no evidence of a primary lesion, axillary lymph node dissection needs to be carried out, and the patient should be offered the choice of radiation therapy or mastectomy followed by proper systemic therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12282-009-0097-9 | DOI Listing |
Front Immunol
December 2024
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Objective: To explore the value of combined radiomics and deep learning models using different machine learning algorithms based on mammography (MG) and magnetic resonance imaging (MRI) for predicting axillary lymph node metastasis (ALNM) in breast cancer (BC). The objective is to provide guidance for developing scientifically individualized treatment plans, assessing prognosis, and planning preoperative interventions.
Methods: A retrospective analysis was conducted on clinical and imaging data from 270 patients with BC confirmed by surgical pathology at the Third Hospital of Shanxi Medical University between November 2022 and April 2024.
J Surg Oncol
December 2024
Section of Plastic and Reconstructive Surgery, University of Chicago Medicine & Biological Sciences, Chicago, Illinois, USA.
Background And Objectives: Immediate lymphatic reconstruction (ILR) performed to prevent breast cancer related lymphedema is not consistently covered by insurance payors in the United States.
Methods: Retrospective review was performed on a prospective database of ILR candidates from 2018 to 2022. Candidates were identified as patients with clinical axillary lymph node involvement at the time of breast cancer diagnosis.
J Plast Reconstr Aesthet Surg
December 2024
Department of Plastic Surgery, and Hospital de Sant Pau, Barcelona, Spain. Electronic address:
Current surgical treatment for established lymphedema can be challenging and not always successful. To reduce the incidence of post-operative lymphedema, we began trialing targeted lymphatic axillary repair (TLAR) as a technique for immediate lymphatic reconstruction with the aim of reducing post-operative lymphedema incidence. In this observational prospective study, conducted between March 2017 and May 2022, we assessed the effectiveness of TLAR in reducing lymphedema occurrence in consecutive breast cancer patients who underwent surgery involving axillary lymph node dissection (ALND).
View Article and Find Full Text PDFInt J Surg Case Rep
December 2024
Department of Surgical Oncology, Regional Hospital of Jendouba, Jendouba, Tunisia.
Introduction: Rosai-Dorfman disease (RDD) is a rare histiocytic neoplasm. It most commonly presents with bilateral cervical lymphadenopathy. We report the fourth case in the literature of RDD presenting as isolated axillary lymphadenopathy.
View Article and Find Full Text PDFThorac Cancer
December 2024
Breast Disease Center, Peking University People's Hospital, Beijing, China.
Background: Sentinel lymph node biopsy (SLNB) using radioisotope tracer plus blue dye is the gold standard after neoadjuvant chemotherapy (NAC) in initially cN1 breast cancer patients, but clinical use still has limitations. This study aims to examine diagnostic performance of dual indocyanine green (ICG) and methylene blue tracing for SLNB in patients who have completed NAC for breast cancer with initially cN1 disease.
Methods: Adult women (20-80 years of age) scheduled to undergo NAC for biopsy-proven cT0-3N1M0 primary invasive breast cancer were consecutively enrolled in this prospective, multicenter, cohort study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!